M. Yarchoan, A. Hopkins, and E. M. Jaffee, Tumor mutational burden and response rate to PD-1 inhibition, N Engl J Med, vol.377, pp.2500-2501, 2017.
DOI : 10.1056/nejmc1713444

A. Ribas and J. D. Wolchok, Cancer immunotherapy using checkpoint blockade, Science, vol.359, pp.1350-1355, 2018.
DOI : 10.1126/science.aar4060

URL : http://science.sciencemag.org/content/sci/359/6382/1350.full.pdf

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, vol.378, pp.158-68, 2018.

D. B. Johnson, S. Chandra, and J. A. Sosman, Immune checkpoint inhibitor toxicity in 2018, JAMA, 2018.

D. Y. Wang, J. E. Salem, and J. V. Cohen, Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis, JAMA Oncol, 2018.

D. B. Johnson, V. Saranga-perry, and P. J. Lavin, Myasthenia gravis induced by Ipilimumab in patients with metastatic melanoma, J Clin Oncol, vol.33, pp.122-126, 2015.

J. Larkin, B. Chmielowski, and C. D. Lao, Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis, Oncologist, vol.22, pp.709-727, 2017.

L. Spain, G. Walls, and M. Julve, Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single Centre experience and review of the literature, Ann Oncol, vol.28, pp.377-85, 2017.

C. A. Garcia, A. El-ali, and T. J. Rath, Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases, J Immunother Cancer, vol.6, p.83, 2018.

L. Zimmer, S. M. Goldinger, and L. Hofmann, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur J Cancer, vol.60, pp.210-235, 2016.

S. Cuzzubbo, F. Javeri, and M. Tissier, Neurological adverse events associated with immune checkpoint inhibitors: review of the literature, Eur J Cancer, vol.73, pp.1-8, 2017.

J. J. Moslehi, J. E. Salem, and J. A. Sosman, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis, Lancet, vol.391, p.933, 2018.

C. Anquetil, J. E. Salem, and B. Lebrun-vignes, Immune checkpoint inhibitorassociated myositis, Circulation, vol.138, pp.743-748, 2018.

J. J. Wright, J. E. Salem, and D. B. Johnson, Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care, 2018.

L. Arnaud, B. Lebrun-vignes, and J. E. Salem, Checkpoint inhibitor-associated immune arthritis, Ann Rheum Dis, 2018.
DOI : 10.1136/annrheumdis-2018-213470

J. E. Salem, A. Manouchehri, and M. Moey, Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study, Lancet Oncol, 2018.

M. Lindquist and . Vigibase, the WHO global ICSR database system: basic facts, vol.42, pp.409-428, 2008.

A. Bate, M. Lindquist, and I. R. Edwards, A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol, vol.54, pp.315-336, 1998.

G. N. Noren, J. Hopstadius, and A. Bate, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery, Stat Methods Med Res, vol.22, pp.57-69, 2013.

M. L. De-bruin, M. Pettersson, and R. H. Meyboom, Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death, Eur Heart J, vol.26, pp.590-597, 2005.

K. J. Rothman, S. Lanes, and S. T. Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiol Drug Saf, vol.13, pp.519-542, 2004.

V. Grouthier, B. Lebrun-vignes, and A. M. Glazer, Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors, Heart, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01971724

A. Nylander and D. A. Hafler, Multiple sclerosis, J Clin Invest, vol.122, pp.1180-1188, 2012.

M. E. Mccauley and R. H. Baloh, Inflammation in ALS/FTD pathogenesis, Acta Neuropathol, 2018.

A. Mishra and R. D. Brinton, Inflammation: bridging age, menopause and APOEepsilon4 genotype to Alzheimer's disease, Front Aging Neurosci, vol.10, p.312, 2018.
DOI : 10.3389/fnagi.2018.00312

URL : https://www.frontiersin.org/articles/10.3389/fnagi.2018.00312/pdf

X. Hu, R. K. Leak, and A. W. Thomson, Promises and limitations of immune cellbased therapies in neurological disorders, Nat Rev Neurol, vol.14, pp.559-68, 2018.

D. B. Johnson, J. M. Balko, and M. L. Compton, Fulminant myocarditis with combination immune checkpoint blockade, N Engl J Med, vol.375, pp.1749-55, 2016.
DOI : 10.1056/nejmoa1609214

URL : http://europepmc.org/articles/pmc5247797?pdf=render